Sildenafil

also known as Sildenafil Citrate · Viagra · Revatio · Hezkue · ASP-001 · Respatio · Respatio(R) · Revation · +6 more

targets CYP3A4 via inhibition

Developed for: erectile dysfunction · pulmonary arterial hypertension · pulmonary hypertension · hypertensive disorder · pulmonary hypertension, neonatal · chronic obstructive pulmonary disease · cystic fibrosis · fetal growth restriction
+133 more
· idiopathic pulmonary fibrosis · congenital heart disease · obesity disorder · sexual disorder · sickle cell disease · congestive heart failure · Duchenne muscular dystrophy · female infertility · intracranial vasospasm · premature ejaculation · pulmonary emphysema · subarachnoid hemorrhage · traumatic brain injury · traumatic encephalopathy · type 2 diabetes mellitus · Becker muscular dystrophy · brain neoplasm · cirrhosis of liver · COVID-19 · depressive disorder · diabetes mellitus · dysmenorrhea · hand-foot syndrome · heart failure · high altitude pulmonary edema · infertility disorder · left ventricular failure · metabolic syndrome X · Parkinson disease · perinatal asphyxia · peripheral arterial occlusive disease 1 · preeclampsia · pulmonary fibrosis · respiratory failure · acute kidney injury · acute mountain sickness · advanced heart failure · age-related macular degeneration · alopecia areata · androgenetic alopecia · anovulation · aortic valve stenosis · atherosclerosis · brain hypoxia - ischemia · breast cancer · bronchopulmonary dysplasia · cancer · cerebrovascular disorder · congenital cardiovascular shunt · diabetic neuropathy · diaphragm disorder · diastolic heart failure · digestive system cancer · Eisenmenger syndrome · endometrial disorder · female reproductive organ cancer · fibrotic liver disease · glioblastoma · glucose intolerance · grade III glioma · habitual spontaneous abortion · hepatic encephalopathy · hypoactive sexual desire disorder · ischemic stroke · kidney cancer · lymphangioma · lymphatic malformation · major depressive disorder · Meniere disease · mitral valve disorder · myalgic encephalomeyelitis/chronic fatigue syndrome · myelodysplastic syndrome · NAFLD1 · neoplasm · nephrogenic diabetes insipidus · peripheral arterial disease · pregnancy loss, recurrent, 4 · priapism · prostatitis · psychosexual disorder · pulmonary embolism · pulmonary immaturity · pulmonary non-tuberculous mycobacterial infection · Raynaud disease · rheumatic heart disease · rheumatoid arthritis · sarcoma · schizophrenia · scleroderma · spinal cord injury · stroke disorder · symptomatic heart failure · systolic heart failure · ulcer disease · univentricular heart · Waldenstrom macroglobulinemia · benign prostatic hyperplasia · beta thalassemia · central serous chorioretinopathy · cholangiocarcinoma · chronic prostatitis · congenital diaphragmatic hernia · coronary vasospasm · diffuse scleroderma · heart disorder · hypoplastic left heart syndrome · impaired renal function disease · limited systemic sclerosis · lung disorder · malignant pancreatic neoplasm · meconium aspiration syndrome · mild pre-eclampsia · moderate heart failure · myopathy · non-small cell lung carcinoma · obstetric disorder · oligohydramnios · optic choroid disorder · persistent fetal circulation syndrome · pregnancy disorder · pulmonary edema · pulmonary hypertension owing to lung disease and/or hypoxia · rectal cancer · retinitis pigmentosa · systemic sclerosis · thalassemia · thrombotic disease · tricuspid atresia · ureterolithiasis · urolithiasis · vascular brain injury · vascular disorder · vitelliform macular dystrophy
Investigated by: Viatris Inc. · Pfizer · Ain Shams University · National Heart, Lung, and Blood Institute (NHLBI) · National Institutes of Health (NIH) · Duke University
+199 more
· Assiut University · Aspargo Labs, Inc · Beni-Suef University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · University of Edinburgh · Vanderbilt University · Ann & Robert H Lurie Children's Hospital of Chicago · Danish Headache Center · Eric A. Hoffman · Johns Hopkins University · Massachusetts General Hospital · National Cancer Institute (NCI) · National Jewish Health · NuSirt Biopharma · Rambam Health Care Campus · Strategic Science & Technologies, LLC · The University of Texas Medical Branch, Galveston · Vanderbilt University Medical Center · Virginia Commonwealth University · Washington University School of Medicine · Actelion · Boston University · CTC Bio, Inc. · Cedars-Sinai Medical Center · Eli Lilly and Company · Hanmi Pharmaceutical Company Limited · Imperial College London · National Center for Research Resources (NCRR) · National Taiwan University Hospital · Novartis Pharmaceuticals · Rigshospitalet, Denmark · Seoul National University Hospital · Stanford University · Symyoo · Tehran University of Medical Sciences · The Emmes Company, LLC · Uniformed Services University of the Health Sciences · University Hospital, Angers · University Hospital, Grenoble · University of Aarhus · University of Alberta · University of Cambridge · University of Colorado, Denver · University of New Mexico · University of North Carolina, Chapel Hill · University of Utah · Aarhus University Hospital · Alicia Gerke · Altitude Physiology Expeditions · Amsterdam UMC, location VUmc · Antoni van Leeuwenhoek Hospital · Asan Medical Center · Assistance Publique - Hôpitaux de Paris · Augusta University · BDD Pharma Ltd · Barnes-Jewish Hospital · Bayer · Berger, Richard E., M.D. · Beth Israel Deaconess Medical Center · Bial - Portela C S.A. · Bio-innova Co., Ltd · Bispebjerg Hospital · Bristol-Myers Squibb · British Heart Foundation · Cairo University · Canadian Institutes of Health Research (CIHR) · Center for Neuroscience and Regenerative Medicine (CNRM) · Charite University, Berlin, Germany · Charles Drew University of Medicine and Science · Children's Hospital Los Angeles · Children's Hospital Medical Center, Cincinnati · Children's Mercy Hospital Kansas City · Chinese Academy of Medical Sciences, Fuwai Hospital · City of Hope Medical Center · all 205 on the full record

Regulatory milestones approvals, filings & regulatory actions · 7 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (4)	US (FDA)	REVATIO	—	2009-05-07 – 2023-01-31	fda.gov ↗
Label expansion	US (FDA)	VIAGRA	—	2002-09-19	fda.gov ↗
Approved	EU (EMA)	Viagra	—	1998-09-13	europa.eu ↗
Approved	US (FDA)	VIAGRA	—	1998-03-27	fda.gov ↗

Trials 265 · started per year

today

US approved 1998

EU approved 1998

19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 07 trials · 1 met primary
Phase 0	NCT07039760	Oct 2026 → Apr 2028 expected	brain neoplasm	Washington University School of Medicine	Not yet recruiting	No outcome recorded
Phase 0	NCT05466695	Aug 2022 → Jul 2023	—	Assiut University	Unknown	No outcome recorded
Phase 0	NCT06527729	Jul 2021 → Jun 2022	alopecia areata	Assiut University	Completed	No outcome recorded
Phase 0	NCT03229512	Apr 2017 → Jun 2020	hand-foot syndrome	Northwestern University	Completed	No outcome recorded
Phase 0	NCT02795351	Jun 2015 → Feb 2021	migraine with aura	Herlev Hospital	Completed	Met primary
Phase 0	NCT01359670	May 2011 → May 2013	Duchenne muscular dystrophy	Cedars-Sinai Medical Center	Completed	No outcome recorded
Phase 0	NCT00815646	Jan 2008 → Dec 2015	high altitude pulmonary edema	Duke University	Completed	No outcome recorded
Phase 148 trials · 1 met primary
Phase 1	NCT07508358	Oct 2026 → Jun 2027 expected	dysmenorrhea, endometriosis, uterine corpus leiomyoma	Kevin Hellman	Not yet recruiting	No outcome recorded
Phase 1	NCT07302698	Mar → May 2026 overdue	—	Aspargo Labs, Inc	Not yet recruiting	No outcome recorded
Phase 1	NCT07117383	Jan → Mar 2026 overdue	erectile dysfunction	Aspargo Labs, Inc	Not yet recruiting	No outcome recorded
Phase 1	NCT06289881	Feb → Mar 2025	—	Bio-innova Co., Ltd	Unknown	No outcome recorded
Phase 1	NCT06782659	Jan → Mar 2025 overdue	erectile dysfunction	Aspargo Labs, Inc	Not yet recruiting	No outcome recorded
Phase 1	NCT06324396	Mar 2024 → Dec 2026 expected	congenital cardiovascular shunt	Children's Mercy Hospital Kansas City	Recruiting	No outcome recorded
Phase 1	NCT05684289	Jan → May 2023	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT05275725	Jul 2022 → Jan 2025	perinatal asphyxia	Pia Wintermark	Completed	No outcome recorded
Phase 1	NCT04283435	Sep 2021 → Mar 2022	—	Cairo University	Unknown	No outcome recorded
Phase 1	NCT04211272	Jan 2020 → Apr 2021	—	Actelion	Completed	No outcome recorded
Phase 1	NCT04169191	Sep 2019 → Dec 2021	perinatal asphyxia	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 1	NCT04481789	Oct → Dec 2018	—	Shionogi	Completed	No outcome recorded
Phase 1	NCT03510338	May → Jun 2018	erectile dysfunction	N4 Pharma UK Ltd.	Completed	No outcome recorded
Phase 1	NCT04994860	Mar → Jun 2018	pulmonary arterial hypertension	Bial - Portela C S.A.	Completed	No outcome recorded
Phase 1	NCT03417492	Mar 2018 → Jun 2022	traumatic brain injury, traumatic encephalopathy	University of Pennsylvania	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02975037	Feb → Mar 2017	—	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT03028298	Dec 2016 → Dec 2022	intracranial vasospasm, subarachnoid hemorrhage	University of Mississippi Medical Center	Unknown	No outcome recorded
Phase 1	NCT02946944	Oct 2016 → Oct 2020	pulmonary embolism	Meshalkin Research Institute of Pathology of Circulation	Unknown	No outcome recorded
Phase 1	NCT02466802	Jul 2015 → Jan 2019	neoplasm	Virginia Commonwealth University	Completed	No outcome recorded
Phase 1	NCT01954524	May 2014 → Oct 2015	cirrhosis of liver	University of Maryland, Baltimore	Terminated	No outcome recorded Stop: Business
Phase 1	NCT02028598	Jan → Mar 2014	—	CTC Bio, Inc.	Completed	No outcome recorded
Phase 1	NCT01986673	Oct → Nov 2013	—	Strategic Science & Technologies, LLC	Completed	No outcome recorded
Phase 1	NCT01950923	Sep 2013 → Mar 2016	kidney cancer	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1	NCT02136329	Jun 2013 → Dec 2014	acute kidney injury	University of Leicester	Completed	No outcome recorded
Phase 1	NCT01670136	Feb 2013 → Jul 2016	pulmonary hypertension, neonatal	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT01499498	Dec 2012 → Apr 2013	hepatitis C virus infection	Imperial College London	Completed	No outcome recorded
Phase 1	NCT01656798	Aug 2012	—	Viatris Inc.	Completed	No outcome recorded
Phase 1	NCT02628847	Mar 2012 → Oct 2016	stroke disorder	University of Utah	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT01580501	Mar 2012 → Mar 2013	Duchenne muscular dystrophy	Cedars-Sinai Medical Center	Completed	No outcome recorded
Phase 1	NCT01651858	Feb → Mar 2012	—	Daewoong Pharmaceutical Co. LTD.	Completed	No outcome recorded
Phase 1	NCT01514903	Dec 2011	erectile dysfunction	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 1	NCT01769638	Sep → Nov 2011	—	Seoul Pharma Co., Ltd.	Completed	Met primary
Phase 1	NCT01375699	Aug 2011 → Aug 2017	breast cancer, digestive system cancer, female reproductive organ cancer, sarcoma	Virginia Commonwealth University	Completed	No outcome recorded
Phase 1	NCT01254396	Dec 2010 → Jan 2011	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 1	NCT01254383	Dec 2010 → Mar 2011	erectile dysfunction	Viatris Inc.	Completed	Mixed
Phase 1	NCT01244620	Nov → Dec 2010	pulmonary arterial hypertension	Pfizer	Terminated	No outcome recorded
Phase 1	NCT01219023	Jun 2010 → Apr 2012	hand-foot syndrome	Duke University	Completed	No outcome recorded
Phase 1	NCT00904748	Jan → Mar 2010	erectile dysfunction	Viatris Inc.	Completed	Mixed
Phase 1	NCT01027117	Sep 2009	—	Viatris Inc.	Completed	No outcome recorded
Phase 1	NCT00950404	Aug → Sep 2009	—	Viatris Inc.	Completed	No outcome recorded
Phase 1	NCT00795938	Oct → Nov 2008	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 1	NCT00866463	Oct 2008	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 1	NCT00814736	Aug → Sep 2008	erectile dysfunction, hyperplasia, overactive bladder	Pfizer	Completed	No outcome recorded
Phase 1	NCT00767598	Dec 2007	—	Inje University	Completed	No outcome recorded
Phase 1	NCT00452582	Apr 2005 → ?	ischemic stroke	Henry Ford Health System	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00056433	Mar 2003 → Dec 2006	sickle cell disease	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 1	NCT00175981	Feb 2003 → Nov 2004	—	Heidelberg University	Completed	No outcome recorded
Phase 1	NCT00223717	Jan 2001 → Jan 2017	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded

Phase 1/213 trials · 1 met primary · 2 missed
Phase 1/2	NCT04489446	Aug 2020 → Apr 2021	COVID-19	Universidad Nacional Andres Bello	Completed	Missed primary
Phase 1/2	NCT04100759	Jun 2019	erectile dysfunction	Ain Shams University	Completed	No outcome recorded
Phase 1/2	NCT03259516	May 2017 → Dec 2018	myelodysplastic syndrome	St. Petersburg State Pavlov Medical University	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT03012386	Jan 2017 → Jul 2021	—	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 1/2	NCT02626182	Dec 2015 → Jan 2018	cystic fibrosis	National Jewish Health	Completed	No outcome recorded
Phase 1/2	NCT03192709	Feb 2015 → Aug 2017	female infertility	Royan Institute	Unknown	No outcome recorded
Phase 1/2	NCT01853540	Jan 2013 → Oct 2014	pulmonary non-tuberculous mycobacterial infection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT01194232	Aug → Dec 2012	cystic fibrosis	Children's Hospital Medical Center, Cincinnati	Withdrawn	No outcome recorded Stop: Business
Phase 1/2	NCT02028429	Jul 2012 → Nov 2013	hepatic encephalopathy	Post Graduate Institute of Medical Education and Research, Chandigarh	Unknown	No outcome recorded
Phase 1/2	NCT01334554	Apr 2011 → Aug 2013	metabolic syndrome X, obesity disorder	Vanderbilt University Medical Center	Completed	Missed primary
Phase 1/2	NCT01290484	Dec 2010 → Apr 2013	lymphangioma	Stanford University	Completed	No outcome recorded
Phase 1/2	NCT00659529	Aug 2008 → Aug 2012	cystic fibrosis	National Jewish Health	Completed	No outcome recorded
Phase 1/2	NCT00123162	May 2007 → Jun 2011	dysmenorrhea	Milton S. Hershey Medical Center	Completed	Met primary

Phase 251 trials · 1 met primary · 10 missed
Phase 2	NCT07647003	Oct 2026 → May 2027 expected	hypertensive disorder	NuSirt Biopharma	Not yet recruiting	No outcome recorded
Phase 2	NCT06810284	Oct 2026 → Jun 2027 expected	brain hypoxia - ischemia	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 2	NCT07290400	Apr → Jun 2026 overdue	erectile dysfunction	Aspargo Labs, Inc	Not yet recruiting	No outcome recorded
Phase 2	NCT05061368	Mar 2022 → May 2027 expected	chronic obstructive pulmonary disease	University of Alberta	Recruiting	No outcome recorded
Phase 2	NCT04797286	Sep 2021 → Nov 2026 expected	pulmonary hypertension, scleroderma	Johns Hopkins University	Recruiting	No outcome recorded
Phase 2	NCT04565925	Jul 2021 → Dec 2026 expected	spinal cord injury	The University of Texas Medical Branch, Galveston	Active not recruiting	No outcome recorded
Phase 2	NCT04985929	Jul 2021 → Jul 2024	—	University of Alberta	Completed	No outcome recorded
Phase 2	NCT04948151	Jun → Dec 2021	sexual disorder	Strategic Science & Technologies, LLC	Unknown	Missed primary
Phase 2	NCT04058132	Aug 2019 → Mar 2020	traumatic brain injury	Uniformed Services University of the Health Sciences	Terminated	No outcome recorded Stop: Business
Phase 2	NCT03855332	Jul 2019 → Dec 2022	cerebrovascular disorder	University of Oxford	Completed	Missed primary
Phase 2	NCT03696758	Oct 2018 → Feb 2020	pulmonary immaturity	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 2	NCT04718233	Sep 2018 → Jul 2019	pregnancy loss, recurrent, 4	Ain Shams University	Completed	No outcome recorded
Phase 2	NCT03142568	Apr 2018 → Mar 2025	bronchopulmonary dysplasia	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT03364335	Jan → Aug 2018	obesity disorder	NuSirt Biopharma	Completed	Met primary
Phase 2	NCT02908490	Apr 2017 → Jun 2020	atherosclerosis, rheumatoid arthritis	Kimberly Liang	Terminated	Missed primary Stop: Enrollment
Phase 2	NCT02951429	Dec 2016 → Sep 2019	idiopathic pulmonary fibrosis	Hoffmann-La Roche	Completed	Missed primary
Phase 2	NCT02663830	Jan 2016 → Jan 2017	anovulation	Ain Shams University	Completed	No outcome recorded
Phase 2	NCT02546609	Nov 2015 → Nov 2016	NAFLD1	NuSirt Biopharma	Completed	Missed primary
Phase 2	NCT02571101	Nov 2015 → May 2016	premature ejaculation	CTC Bio, Inc.	Unknown	No outcome recorded
Phase 2	NCT01132482	Oct 2015 → May 2017	cystic fibrosis	National Jewish Health	Completed	No outcome recorded
Phase 2	NCT02570282	Sep 2015 → May 2017	sexual disorder	Strategic Science & Technologies, LLC	Completed	No outcome recorded
Phase 2	NCT02335242	May 2015 → Mar 2021	lymphatic malformation	Stanford University	Completed	No outcome recorded
Phase 2	NCT02244528	Oct 2014 → Oct 2016	—	Seoul National University Hospital	Completed	No outcome recorded
Phase 2	NCT02057458	Apr 2014 → Jul 2018	cystic fibrosis	Augusta University	Completed	No outcome recorded
Phase 2	NCT01817751	Apr 2013 → Aug 2020	brain neoplasm, glioblastoma, grade III glioma	Virginia Commonwealth University	Completed	No outcome recorded
Phase 2	NCT01830790	Mar 2013 → May 2014	age-related macular degeneration	Duke University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01762475	Jan 2013 → Dec 2015	traumatic brain injury, traumatic encephalopathy	Uniformed Services University of the Health Sciences	Completed	No outcome recorded
Phase 2	NCT01601470	Sep 2012 → Jan 2013	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01360671	Mar 2012 → Apr 2013	pulmonary hypertension, neonatal	Viatris Inc.	Withdrawn	No outcome recorded
Phase 2	NCT01481350	Feb 2012 → Jun 2013	pulmonary hypertension	University of Turin, Italy	Completed	No outcome recorded
Phase 2	NCT01350154	Nov 2011 → Apr 2013	Becker muscular dystrophy	Rigshospitalet, Denmark	Completed	No outcome recorded
Phase 2	NCT01432665	Sep 2011 → May 2013	hypoactive sexual desire disorder	Emotional Brain NY Inc.	Completed	No outcome recorded
Phase 2	NCT01409031	Jul 2011 → Oct 2013	pulmonary hypertension, respiratory failure	University of Colorado, Denver	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01069861	Dec 2010 → Nov 2011	pulmonary hypertension, neonatal, respiratory failure	Viatris Inc.	Terminated	No outcome recorded
Phase 2	NCT01168908	Sep 2010 → Jan 2014	Becker muscular dystrophy, Duchenne muscular dystrophy	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Terminated	Missed primary
Phase 2	NCT01091870	Mar 2010 → Dec 2012	brain aneurysm, intracranial vasospasm, subarachnoid hemorrhage	Hospital de Clinicas de Porto Alegre	Withdrawn	No outcome recorded
Phase 2	NCT00914277	May → Sep 2009	erectile dysfunction	Sanofi	Completed	No outcome recorded
Phase 2	NCT00871065	Jul 2008 → Feb 2009	intracranial vasospasm, subarachnoid hemorrhage	University of Nebraska	Withdrawn	No outcome recorded
Phase 2	NCT00940901	Jun 2008 → Nov 2012	priapism, sickle cell disease	Johns Hopkins University	Completed	Missed primary
Phase 2	NCT00492531	Jun 2007 → Sep 2009	pulmonary hypertension, sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Terminated	Missed primary
Phase 2	NCT00359736	Jul 2006 → Oct 2008	pulmonary fibrosis, pulmonary hypertension	VA Office of Research and Development	Completed	Missed primary
Phase 2	NCT00273416	Jan 2006 → ?	erectile dysfunction	Pfizer	Completed	No outcome recorded
Phase 2	NCT00165295	Sep 2005 → Jun 2007	Waldenstrom macroglobulinemia	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00352482	Nov 2004 → Jul 2007	idiopathic pulmonary fibrosis, pulmonary hypertension	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00141310	Sep 2004 → Apr 2006	preeclampsia	Viatris Inc.	Terminated	Missed primary
Phase 2	NCT00640458	Apr 2004 → Mar 2007	sexual disorder	Viatris Inc.	Completed	No outcome recorded
Phase 2	NCT00317421	Mar 2004 → Nov 2005	hypertensive disorder	University of Edinburgh	Completed	No outcome recorded
Phase 2	NCT00624273	Feb → Nov 2004	ulcer disease	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 2	NCT00145938	Sep 2003 → Sep 2006	pulmonary hypertension	University of Chicago	Terminated	No outcome recorded
Phase 2	NCT00746967	Jan 2003 → Feb 2004	psychosexual disorder	Viatris Inc.	Completed	No outcome recorded
Phase 2	NCT02162979	Feb 2002 → Jan 2009	Parkinson disease	Loma Linda University	Terminated	No outcome recorded

Phase 2/314 trials
Phase 2/3	NCT06800092	Jun 2027 → Jun 2030 expected	cancer	The University of Texas Medical Branch, Galveston	Not yet recruiting	No outcome recorded
Phase 2/3	NCT07824674	Sep 2026 → Apr 2028 expected	pulmonary arterial hypertension	Silvia Ulrich	Recruiting	No outcome recorded
Phase 2/3	NCT07462260	Aug 2025 → Sep 2026	pulmonary hypertension, rheumatic heart disease	Sindh Institute of Cardiovascular Diseases	Completed	No outcome recorded
Phase 2/3	NCT05971667	Jul → Oct 2023	—	Beni-Suef University	Unknown	No outcome recorded
Phase 2/3	NCT05951413	Jun → Sep 2023	—	Beni-Suef University	Unknown	No outcome recorded
Phase 2/3	NCT05846906	Oct 2021 → Apr 2022	female infertility	Beni-Suef University	Completed	No outcome recorded
Phase 2/3	NCT03763045	Dec 2018 → Feb 2019	pulmonary hypertension	Ain Shams University	Unknown	No outcome recorded
Phase 2/3	NCT02782559	Jul 2016 → Jul 2017	preeclampsia	The University of Texas Health Science Center, Houston	Withdrawn	No outcome recorded Stop: Business
Phase 2/3	NCT02435303	May 2016 → Jun 2018	mitral valve disorder, pulmonary hypertension	Asan Medical Center	Terminated	No outcome recorded
Phase 2/3	NCT02766725	Jan → Nov 2015	infertility disorder	Assiut University	Completed	No outcome recorded
Phase 2/3	NCT02050360	Nov 2013 → May 2015	Raynaud disease	University Hospital, Grenoble	Completed	No outcome recorded
Phase 2/3	NCT01936350	Sep → Nov 2013	heart failure	Hospital Ana Nery	Completed	No outcome recorded
Phase 2/3	NCT00981747	Sep 2009 → Dec 2016	idiopathic pulmonary fibrosis, pulmonary fibrosis	Alicia Gerke	Terminated	No outcome recorded Stop: Business
Phase 2/3	NCT01107782	Jun 2008 → Jun 2010	fetal growth restriction	Tehran University of Medical Sciences	Unknown	No outcome recorded

Phase 333 trials · 2 met primary · 5 missed
Phase 3	NCT05490680	Jan → Dec 2024	erectile dysfunction	IBSA Institut Biochimique SA	Completed	No outcome recorded
Phase 3	NCT03997097	Jun 2023 → Jun 2026	pulmonary hypertension, univentricular heart	University Hospital, Montpellier	Withdrawn	No outcome recorded
Phase 3	NCT03686306	Nov 2021 → Nov 2025 overdue	peripheral arterial disease	Rennes University Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT04304313	Feb → Mar 2020	COVID-19	Tongji Hospital	Unknown	No outcome recorded
Phase 3	NCT04052269	Jun 2019 → Oct 2021	glaucoma	Imperial College London	Suspended	No outcome recorded
Phase 3	NCT03356353	Mar 2018 → Sep 2021	advanced heart failure	University of Calgary	Unknown	No outcome recorded
Phase 3	NCT03154476	Jul 2017 → Jun 2019	cirrhosis of liver, congenital heart disease	Mayo Clinic	Completed	No outcome recorded
Phase 3	NCT03230162	Jun 2017 → May 2018	fetal growth restriction	Ain Shams University	Unknown	No outcome recorded
Phase 3	NCT03177824	Mar → Sep 2017	fetal growth restriction	Ain Shams University	Unknown	No outcome recorded
Phase 3	NCT02832570	Nov 2016 → Oct 2017	peripheral arterial occlusive disease 1	University Hospital, Angers	Completed	Met primary
Phase 3	NCT02590536	Oct 2015 → Jun 2017	fetal growth restriction	Ain Shams University	Completed	No outcome recorded
Phase 3	NCT01913847	Sep 2013 → Dec 2018	pulmonary hypertension, systolic heart failure	Hanmi Pharmaceutical Company Limited	Unknown	No outcome recorded
Phase 3	NCT01720524	Aug 2013 → Oct 2018	pulmonary hypertension, neonatal	Viatris Inc.	Completed	Missed primary
Phase 3	NCT01091012	Sep 2011 → Dec 2012	pulmonary hypertension	Hospital Universitari Vall d'Hebron Research Institute	Unknown	No outcome recorded
Phase 3	NCT01392469	Apr 2011 → Oct 2012	pulmonary arterial hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00796510	Jul 2010 → Jan 2011	pulmonary arterial hypertension	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00796666	May 2009 → Mar 2011	pulmonary arterial hypertension	Pfizer	Terminated	Missed primary
Phase 3	NCT00763867	Sep 2008 → Sep 2012	diastolic heart failure	Duke University	Completed	Missed primary
Phase 3	NCT00734604	Aug 2008 → Sep 2009	erectile dysfunction	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00742014	Aug 2008 → Aug 2011	hypertensive disorder	The Hospital for Sick Children	Terminated	No outcome recorded
Phase 3	NCT00454207	Apr 2007 → Feb 2009	pulmonary arterial hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00303004	Mar 2006 → Jan 2008	Eisenmenger syndrome	Rigshospitalet, Denmark	Completed	Missed primary
Phase 3	NCT00544076	Jan 2006 → Apr 2012	erectile dysfunction, grade III prostatic intraepithelial neoplasia	City of Hope Medical Center	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00407446	Jan 2004 → Feb 2005	heart failure	University of Milan	Completed	No outcome recorded
Phase 3	NCT00159874	Jan 2004 → Dec 2012	pulmonary arterial hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00159913	Aug 2003 → Jun 2008	pulmonary arterial hypertension	Viatris Inc.	Completed	Missed primary
Phase 3	NCT00159861	Jul 2003 → Jan 2006	pulmonary hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00309790	May 2003 → Mar 2006	congestive heart failure	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00159887	Dec 2002 → Feb 2007	pulmonary arterial hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00309816	Dec 2001 → Feb 2006	congestive heart failure	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00527995	Aug 2001 → Jun 2003	type 2 diabetes mellitus	Ruhr University of Bochum	Completed	No outcome recorded
Phase 3	NCT00420901	Jan 1999 → Feb 2000	diabetes mellitus	IRCCS San Raffaele	Completed	No outcome recorded
Phase 3	NCT02930811	? → Oct 2022	peripheral arterial occlusive disease 1	University Hospital, Angers	Withdrawn	No outcome recorded

Phase 465 trials · 4 met primary · 5 missed
Phase 4	NCT06875258	Jan 2024 → Jan 2027 expected	—	The Netherlands Cancer Institute	Recruiting	No outcome recorded
Phase 4	NCT05183334	Dec 2021 → Dec 2022	premature ejaculation	Assiut University	Unknown	No outcome recorded
Phase 4	NCT05753098	Jan 2021 → Jan 2023	female infertility	Beni-Suef University	Completed	No outcome recorded
Phase 4	NCT04325243	Sep 2020 → Apr 2022	—	Assiut University	Completed	No outcome recorded
Phase 4	NCT03382106	Mar 2018 → Sep 2024	pulmonary emphysema	Eric A. Hoffman	Completed	No outcome recorded
Phase 4	NCT02682147	Jul 2017 → May 2025 overdue	pulmonary emphysema	Eric A. Hoffman	Active not recruiting	No outcome recorded
Phase 4	NCT04908657	Jul 2017 → Jul 2023	fibrotic liver disease	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT03044561	Jan → Aug 2017	infertility disorder	Ain Shams University	Unknown	No outcome recorded
Phase 4	NCT02939495	Oct 2016 → Jun 2017	erectile dysfunction, premature ejaculation	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT02524184	Aug 2015 → Sep 2016	obesity disorder	Xiang Guang-da	Unknown	No outcome recorded
Phase 4	NCT02378649	Mar 2015 → Jun 2018	pulmonary hypertension	Dr. Robert Klempfner Heart Rehabilitation Institute	Completed	No outcome recorded
Phase 4	NCT02620995	Oct 2014 → Jan 2018	erectile dysfunction, hypertensive disorder	National Institute of Cardiology, Laranjeiras, Brazil	Completed	No outcome recorded
Phase 4	NCT02060487	Sep 2014 → Feb 2021	pulmonary arterial hypertension	Viatris Inc.	Terminated	Met primary
Phase 4	NCT02129725	Apr 2014 → Oct 2016	metabolic syndrome X	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT03236818	May 2013 → Sep 2017	pulmonary arterial hypertension	Amsterdam UMC, location VUmc	Unknown	No outcome recorded
Phase 4	NCT01889966	Apr 2013 → Jan 2015	pulmonary hypertension	Kerckhoff Heart Center	Completed	No outcome recorded
Phase 4	NCT01800292	Feb → Dec 2013	left ventricular failure, pulmonary arterial hypertension	University of Arizona	Completed	No outcome recorded
Phase 4	NCT01642407	Aug 2012 → May 2016	pulmonary arterial hypertension	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00730067	Jun → Dec 2012	chronic obstructive pulmonary disease, pulmonary hypertension	University of Aarhus	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01419392	Sep 2011 → Apr 2012	habitual spontaneous abortion	Ain Shams University	Unknown	No outcome recorded
Phase 4	NCT01382368	Sep 2011 → Nov 2012	chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis	Rabin Medical Center	Unknown	No outcome recorded
Phase 4	NCT01409993	Aug 2011 → Nov 2016	glucose intolerance	Vanderbilt University	Terminated	No outcome recorded Stop: Business
Phase 4	NCT03733470	Jun 2011 → Jan 2014	pulmonary emphysema	Eric A. Hoffman	Completed	No outcome recorded
Phase 4	NCT01352507	Jun 2011 → Jun 2012	erectile dysfunction	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT01060020	Jan 2010 → Sep 2011	aortic valve stenosis	Washington University School of Medicine	Completed	No outcome recorded
Phase 4	NCT00937144	Sep 2009	sickle cell disease	The Baruch Padeh Medical Center, Poriya	Withdrawn	No outcome recorded
Phase 4	NCT01668446	Sep 2009	endometrial disorder	farzaneh hojjat	Completed	No outcome recorded
Phase 4	NCT00862043	Apr 2009 → Jul 2016	heart valve disorder, pulmonary hypertension	Hospital General Universitario Gregorio Marañon	Completed	Missed primary
Phase 4	NCT00793338	Nov 2008 → Nov 2010	congestive heart failure	University of New Mexico	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT01055405	Aug 2008 → Mar 2011	chronic obstructive pulmonary disease, pulmonary hypertension	Hospital Clinic of Barcelona	Completed	Missed primary
Phase 4	NCT00430716	Apr 2008 → May 2010	pulmonary arterial hypertension	Viatris Inc.	Terminated	Mixed
Phase 4	NCT00433329	Mar 2007 → May 2010	pulmonary arterial hypertension	Actelion	Completed	No outcome recorded
Phase 4	NCT00625079	Feb 2007 → Jun 2009	idiopathic pulmonary fibrosis, pulmonary arterial hypertension	University of California, Los Angeles	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT00781508	Dec 2006 → Sep 2009	left ventricular failure, symptomatic heart failure	MetroHealth Medical Center	Completed	No outcome recorded
Phase 4	NCT00512707	Nov 2006 → May 2010	diabetes mellitus, erectile dysfunction, hypogonadism	Boston University	Completed	Missed primary
Phase 4	NCT00323297	Sep 2006 → Aug 2013	pulmonary arterial hypertension	Viatris Inc.	Completed	Missed primary
Phase 4	NCT00347867	Jul 2006 → ?	fetal growth restriction	Rambam Health Care Campus	Unknown	No outcome recorded
Phase 4	NCT00343200	Jul 2006 → Sep 2007	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00350441	Jun 2006 → ?	—	NHS Greater Glasgow Yorkhill Division	Unknown	No outcome recorded
Phase 4	NCT00133679	Feb 2006 → Jul 2013	diaphragm disorder, pulmonary hypertension, pulmonary hypoplasia	University of California, San Francisco	Terminated	No outcome recorded
Phase 4	NCT00455715	Feb 2006 → Sep 2007	schizophrenia	Massachusetts General Hospital	Completed	Missed primary
Phase 4	NCT00147628	Nov 2005 → Sep 2006	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00301262	Nov 2005 → Sep 2007	erectile dysfunction	Viatris Inc.	Completed	Met primary
Phase 4	NCT00245258	Nov 2005 → Sep 2006	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00249730	Oct 2005 → ?	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00245596	Oct 2005 → ?	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00313898	Sep 2005 → Jun 2007	erectile dysfunction	Rambam Health Care Campus	Unknown	No outcome recorded
Phase 4	NCT00143260	Aug 2005 → May 2006	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00159900	May 2005 → Jan 2006	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00137072	Apr 2005 → Feb 2006	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00150358	Mar → Nov 2005	erectile dysfunction, hypertensive disorder	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00151463	Jan 2005 → ?	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00194909	Aug 2004 → Jul 2006	diabetic neuropathy	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 4	NCT00194597	Jul 2004 → Jul 2007	prostatitis	University of Washington	Terminated	No outcome recorded
Phase 4	NCT00159809	Mar → Aug 2004	depressive disorder, erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00143221	Mar 2004 → May 2005	erectile dysfunction	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00479908	Jan 2004 → Sep 2005	intermediate coronary syndrome	University of Edinburgh	Completed	No outcome recorded
Phase 4	NCT01941732	Nov 2003 → Feb 2004	Parkinson disease, erectile dysfunction	Bispebjerg Hospital	Completed	No outcome recorded
Phase 4	NCT00483626	Aug 2003 → Jun 2007	pulmonary arterial hypertension	University of Chile	Unknown	No outcome recorded
Phase 4	NCT00627965	Mar 2003 → Feb 2008	acute mountain sickness, high altitude pulmonary edema	Altitude Physiology Expeditions	Completed	No outcome recorded
Phase 4	NCT00645268	Dec 2002 → Jan 2004	erectile dysfunction, type 2 diabetes mellitus	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00598585	Jul 2002 → Dec 2010	myalgic encephalomeyelitis/chronic fatigue syndrome	Charles Drew University of Medicine and Science	Completed	Met primary
Phase 4	NCT00145483	Jun 2002 → Nov 2006	Meniere disease	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00251784	Feb 2002 → Jun 2003	blindness (disorder)	University of Cambridge	Completed	No outcome recorded
Phase 4	NCT00375297	Jan 2001 → Jun 2005	depressive disorder, sexual disorder	University of New Mexico	Completed	No outcome recorded

Phase not applicable31 trials · 4 met primary
—	NCT04912726	Jan 2025 → Jun 2026	pulmonary hypertension, neonatal	Universidad del Norte	Withdrawn	No outcome recorded
—	NCT06237751	Feb → Oct 2024	—	First People's Hospital of Chenzhou	Unknown	No outcome recorded
—	NCT06562036	Dec 2023 → May 2024	pulmonary hypertension, neonatal	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT05889455	Apr → Oct 2023	migraine without aura	Danish Headache Center	Completed	No outcome recorded
—	NCT05669885	Jan → Dec 2023	traumatic encephalopathy	Danish Headache Center	Unknown	Met primary
—	NCT05369481	Mar → Aug 2022	androgenetic alopecia	Mohammed Abd El Mawgoud Amer	Unknown	No outcome recorded
—	NCT04122105	Apr 2021 → Jan 2023	—	University of British Columbia	Withdrawn	No outcome recorded
—	NCT04344678	Jan 2020 → Oct 2024	major depressive disorder	Sadat City University	Withdrawn	No outcome recorded Stop: Business
—	NCT04170790	Dec 2019	erectile dysfunction, type 2 diabetes mellitus	Ain Shams University	Unknown	No outcome recorded
—	NCT04126252	Aug 2018 → Sep 2019	erectile dysfunction	International Islamic University, Islamabad	Completed	No outcome recorded
—	NCT03301233	Nov 2017 → Jul 2018	—	Ain Shams University	Completed	No outcome recorded
—	NCT03185364	Jun 2017 → Dec 2020	chronic obstructive pulmonary disease, pulmonary hypertension	Chinese Academy of Medical Sciences, Fuwai Hospital	Unknown	No outcome recorded
—	NCT03143465	Aug 2016 → Dec 2018	migraine with aura	Danish Headache Center	Unknown	No outcome recorded
—	NCT01572363	Apr 2012 → Mar 2014	congenital heart disease	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
—	NCT01548950	Sep 2011 → Jan 2014	congenital heart disease, pulmonary arterial hypertension	University of Sao Paulo General Hospital	Completed	No outcome recorded
—	NCT01373749	Mar → Dec 2011	pulmonary hypertension, neonatal	Third Military Medical University	Unknown	No outcome recorded
—	NCT01812434	Oct 2010 → Mar 2015	—	University of Minnesota	Withdrawn	No outcome recorded
—	NCT01059994	Jan 2010 → Jul 2013	—	The University of Texas Medical Branch, Galveston	Completed	Met primary
—	NCT00955929	Aug 2009 → Dec 2020	erectile dysfunction, penile cancer	Memorial Sloan Kettering Cancer Center	Terminated	No outcome recorded Stop: Enrollment
—	NCT01948518	Jun 2009 → Jun 2012	interstitial lung disease, pulmonary hypertension	The Cleveland Clinic	Completed	No outcome recorded
—	NCT01391104	Apr 2009 → Nov 2011	pulmonary arterial hypertension	Laval University	Completed	No outcome recorded
—	NCT00772135	Sep 2008 → Feb 2009	congenital heart disease	Oslo University Hospital	Unknown	No outcome recorded
—	NCT00710099	Jul 2008 → Jun 2011	—	University Hospital, Grenoble	Completed	No outcome recorded
—	NCT00685945	Dec 2007 → Jan 2009	obesity disorder	Vanderbilt University	Completed	Met primary
—	NCT00507286	May 2007 → Sep 2008	erectile dysfunction	Keogh Institute for Medical Research	Unknown	No outcome recorded
—	NCT00478335	May 2007 → Oct 2012	nephrogenic diabetes insipidus	University of Colorado, Denver	Completed	No outcome recorded
—	NCT00599235	Mar 2007 → May 2008	hypertensive disorder	University of Edinburgh	Completed	No outcome recorded
—	NCT00463957	Aug 2006 → ?	erectile dysfunction	University of Cambridge	Unknown	No outcome recorded
—	NCT00297544	Oct 2005 → ?	erectile dysfunction	Rambam Health Care Campus	Unknown	No outcome recorded
—	NCT00057759	Jan 2003 → Dec 2006	erectile dysfunction, prostate cancer, radiation-induced disorder	Radiation Therapy Oncology Group	Completed	Met primary
—	NCT00155714	Nov 2002 → May 2005	pulmonary hypertension	National Taiwan University Hospital	Withdrawn	No outcome recorded

Phase not stated3 trials
—	NCT01582438	—	pulmonary arterial hypertension	Viatris Inc.	No longer available	No outcome recorded
—	NCT01897740	—	pulmonary arterial hypertension	Viatris Inc.	No longer available	No outcome recorded
—	NCT00866983	—	pulmonary arterial hypertension	Viatris Inc.	No longer available	No outcome recorded
Comparator or background therapy152 trials
Phase 0	NCT06510322 Comparator	Mar 2025 → Dec 2029 expected	vascular disorder	Montefiore Medical Center	Recruiting	No outcome recorded
Phase 0	NCT04770155 Comparator	May → Sep 2021	vascular insufficiency disorder	University of Mississippi Medical Center	Terminated	No outcome recorded
Phase 0	NCT03945643 Comparator	Jul 2019 → Jan 2023	congenital arteriovenous fistula, patent foramen ovale	University of Oregon	Completed	No outcome recorded
Phase 0	NCT03199612 Comparator	Jun 2019 → Jan 2023	hemolytic anemia, thrombotic disease	Montefiore Medical Center	Completed	No outcome recorded
Phase 0	NCT03027674 Comparator	Aug 2016	Raynaud disease, dermatomyositis, systemic lupus erythematosus, systemic sclerosis	Pontificia Universidad Catolica de Chile	Completed	No outcome recorded
Show all 152 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 24

Date	Issuer	Release
2026-09-14	Daré Bioscience, Inc.	Results Press Release: Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil darebioscience.com ↗ Topical dosing is targeted and has been shown to result in substantially lower systemic exposure than an oral dose of sildenafil.
2026-08-26	Daré Bioscience, Inc.	Results Press Release: Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause – The Journal of The Menopause Society darebioscience.com ↗
2026-03-10	Aspargo Labs, Inc	Regulatory Aspargo Labs Gears Up to Bring Patented Liquid Erectile Dysfunction Treatment to UK Over-the-Counter Pharmacy Shelves aspargolabs.com ↗ today announced it has submitted an application to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of a smaller pack size
2026-02-05	IBSA Institut Biochimique SA	Regulatory IBSA Expands Solutions in Male Sexual Health in the US with New FDA Approval ibsagroup.com ↗ The Food and Drug Administration (FDA) approval has been granted for sildenafil oral film .
2024-12-10	Strategic Science & Technologies, LLC	Results Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% strategicscience.com ↗ We were pleased to see that age and race did not significantly impact response to Sildenafil Cream.
2024-08-26	Strategic Science & Technologies, LLC	Results Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% strategicscience.com ↗ Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences.
2024-08-13	Strategic Science & Technologies, LLC	Results Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% strategicscience.com ↗ Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies
2024-06-30	Aspargo Labs, Inc	Results Aspargo Labs Announces Data on First Oral Spray for Erectile Dysfunction, ASP-001, Showing Two Times Faster Absorption Compared to Viagra® Tablets aspargolabs.com ↗ today announced the release of a Phase 1 study demonstrating that ASP-001, an investigative sildenafil oral spray in development for erectile dysfunction (ED), achieves absorption starting within five minutes, twice as fast as traditional sildenafil tablets.
2024-06-24	Strategic Science & Technologies, LLC	Results Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder strategicscience.com ↗ Topical Sildenafil Cream improved outcomes among women with FSAD, most significantly in a subset of women both with and without concomitant decreased desire.
2024-03-07	Strategic Science & Technologies, LLC	Results Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder strategicscience.com ↗
2023-09-05	Aspargo Labs, Inc	Regulatory Aspargo Laboratories Announces IND Clearance by U.S. FDA, Enabling Launch of Bioequivalence and Food-Effect Studies for Sildenafil Oral Spray aspargolabs.com ↗ We are thrilled to have received IND clearance from the FDA for Sildenafil Oral Spray for the treatment of ED.
2023-08-01	Aspargo Labs, Inc	Regulatory Aspargo Laboratories, Inc. Announces Filing of Its Investigational New Drug Application For Sildenafil Oral Spray aspargolabs.com ↗
2023-01-24	Aspargo Labs, Inc	Regulatory Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands aspargolabs.com ↗ Aspargo Laboratories, Inc. (“Aspargo”), a privately held specialty pharmaceutical company focused on commercializing innovative formulations of leading tablet medications, announced today that the German Federal Institute for Drugs and Medical Devices has authorized the marketability of “Hezkue™ 12.5 mg per actuation, oral suspension“ in Germany effective as of January 12, 2023.
2022-10-01	Zydus Lifesciences Limited	Regulatory Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension zyduslife.com ↗ Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has received final approval from the United States Food and Drug Administration (USFDA) to market Sildenafil for Oral Suspension USP 10 mg/ml USRLD: Revatio.
2022-03-24	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Sildenafil for Oral Suspension lupin.com ↗
2022-02-02	Lexaria Bioscience Corp.	Results Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study lexariabioscience.com ↗ In as little as four minutes after dosing, the DehydraTECH formulation delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation.
2019-12-02	Impax Laboratories, LLC	Regulatory Amneal Announces the Approval and Launch of Generic Revatio® for Oral Suspension and Generic Amicar® Tablets amneal.com ↗ today announced that it has received final U.S. Food and Drug Administration (“FDA”) approval on its Abbreviated New Drug Applications (“ANDA”) for generic versions of Revatio® (sildenafil citrate) for Oral Suspension 10 mg/ml and Amicar® (aminocaproic acid) Tablets USP, 500 mg.
2019-08-26	Dicot AB	Results Resultat från jämförande djurförsöksstudie på effekterna av dess kandidatämne Libiguin® DIC2024 kontra den aktiva substansen i Viagra® dicotpharma.com ↗ Både DIC2024 och sildenafil gav en påtaglig stimulering av parningsbeteendet hos försöksdjuren, men resultaten visade också på tydliga skillnader i beteendemönstret, vilket visar att verkningsmekanismerna för preparaten skiljer sig markant.
2019-06-28	Pfizer	Results Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension pfizer.com ↗ Treatment with IV sildenafil when added to iNO did not result in a statistically significant reduction in treatment failure rate or time on iNO compared to treatment with iNO alone.
2019-06-17	Strategic Science & Technologies, LLC	Results Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder strategicscience.com ↗ Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in normal healthy women.
2019-03-25	Lupin Limited	Regulatory Lupin receives FDA approval for Sildenafil Tablets USP lupin.com ↗ Lupin Limited (Lupin) announced that it has received approval for its Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc’s Viagra Tablets, 25 mg, 50 mg, and 100 mg.
2015-11-05	Gilead Sciences	Regulatory U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ Gilead Sciences, Inc. (NASDAQ:GILD) announced today that the U.S. Food and Drug Administration ( FDA ) has approved Genvoya ® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection.
2015-05-15	Strategic Science & Technologies, LLC	Results Strategic Science & Technologies, LLC (SST) announces completion of its Phase 1 clinical trial for SST-6007, a first-in-class topical sildenafil cream, to treat female sexual arousal disorder ------------------------------------------------ • SST-6007 was well tolerated in healthy subjects, with no dermal irritation observed at clinically relevant doses • SST-6007 successfully delivered sildenafil to the local target tissue • SST-6007 was systemically absorbed into the bloodstream, but at significantly reduced levels compared to the marketed oral formulation of sildenafil (Viagra®) ------------------------------------------------ strategicscience.com ↗ SST-6007 was well tolerated in healthy subjects, with no dermal irritation observed at clinically relevant doses
2007-08-10	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Tentative Approval Of Sildenafil Citrate Tablets, 20 Mg tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Sildenafil Citrate Tablets, 20 mg.

All press releases naming this drug 50 releases

Date	Issuer	Release
2026-09-14	Daré Bioscience, Inc.	Press Release: Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil darebioscience.com ↗
2026-08-26	Daré Bioscience, Inc.	Press Release: Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause – The Journal of The Menopause Society darebioscience.com ↗
2026-03-23	Daré Bioscience, Inc.	Press Release: On National Viagra Day, Women Finally Claim Their Turn darebioscience.com ↗
2026-03-10	Aspargo Labs, Inc	Aspargo Labs Gears Up to Bring Patented Liquid Erectile Dysfunction Treatment to UK Over-the-Counter Pharmacy Shelves aspargolabs.com ↗
2026-02-11	Strategic Science & Technologies, LLC	Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women strategicscience.com ↗
2026-02-11	Daré Bioscience, Inc.	Press Release: Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women darebioscience.com ↗
2026-02-05	IBSA Institut Biochimique SA	IBSA Expands Solutions in Male Sexual Health in the US with New FDA Approval ibsagroup.com ↗
2025-11-11	Strategic Science & Technologies, LLC	Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; strategicscience.com ↗
2025-07-29	Strategic Science & Technologies, LLC	Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream strategicscience.com ↗
2025-06-04	Strategic Science & Technologies, LLC	Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream strategicscience.com ↗
2025-04-07	Strategic Science & Technologies, LLC	Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year strategicscience.com ↗
2024-12-16	Strategic Science & Technologies, LLC	Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) strategicscience.com ↗
2024-12-10	Strategic Science & Technologies, LLC	Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% strategicscience.com ↗
2024-09-30	Annovis Bio Inc.	Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra annovisbio.com ↗
2024-08-26	Strategic Science & Technologies, LLC	Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% strategicscience.com ↗
2024-08-13	Strategic Science & Technologies, LLC	Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% strategicscience.com ↗
2024-06-30	Aspargo Labs, Inc	Aspargo Labs Announces Data on First Oral Spray for Erectile Dysfunction, ASP-001, Showing Two Times Faster Absorption Compared to Viagra® Tablets aspargolabs.com ↗
2024-06-24	Strategic Science & Technologies, LLC	Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder strategicscience.com ↗
2024-03-07	Strategic Science & Technologies, LLC	Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder strategicscience.com ↗
2023-12-05	Aspargo Labs, Inc	Aspargo Announces Completion of Dosing of All Subjects in Sildenafil Oral Suspension Bioavailability Study and Initiation of Dosing in Companion Food-Effect Study aspargolabs.com ↗
2023-09-19	Aspargo Labs, Inc	Aspargo Laboratories Inc. Announces Initial Dosing of All Subjects in Bioavailability Study for Sildenafil Oral Suspension aspargolabs.com ↗
2023-09-05	Aspargo Labs, Inc	Aspargo Laboratories Announces IND Clearance by U.S. FDA, Enabling Launch of Bioequivalence and Food-Effect Studies for Sildenafil Oral Spray aspargolabs.com ↗
2023-08-01	Aspargo Labs, Inc	Aspargo Laboratories, Inc. Announces Filing of Its Investigational New Drug Application For Sildenafil Oral Spray aspargolabs.com ↗
2023-01-24	Aspargo Labs, Inc	Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands aspargolabs.com ↗
2022-10-01	Zydus Lifesciences Limited	Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension zyduslife.com ↗
2022-09-29	Lupin Limited	Lupin Launches Sildenafil for Oral Suspension in the United States lupin.com ↗
2022-09-29	Aspargo Labs, Inc	Aspargo Acquires International Rights to Sildenafil Oral Spray aspargolabs.com ↗
2022-05-03	Aspargo Labs, Inc	Aspargo Acquires Bandol® Sildenafil Spray aspargolabs.com ↗
2022-03-24	Lupin Limited	Lupin Receives Approval from U.S. FDA for Sildenafil for Oral Suspension lupin.com ↗
2022-02-02	Lexaria Bioscience Corp.	Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study lexariabioscience.com ↗
2020-01-23	Pfizer	Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate) pfizer.com ↗
2019-12-02	Impax Laboratories, LLC	Amneal Announces the Approval and Launch of Generic Revatio® for Oral Suspension and Generic Amicar® Tablets amneal.com ↗
2019-09-30	Lupin Limited	Lupin launches Sildenafil Tablets USP lupin.com ↗
2019-08-26	Dicot AB	Resultat från jämförande djurförsöksstudie på effekterna av dess kandidatämne Libiguin® DIC2024 kontra den aktiva substansen i Viagra® dicotpharma.com ↗
2019-06-28	Pfizer	Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension pfizer.com ↗
2019-06-17	Strategic Science & Technologies, LLC	Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder strategicscience.com ↗
2019-03-25	Lupin Limited	Lupin receives FDA approval for Sildenafil Tablets USP lupin.com ↗
2018-11-29	Strategic Science & Technologies, LLC	Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder strategicscience.com ↗
2018-11-27	Strategic Science & Technologies, LLC	Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder strategicscience.com ↗
2018-02-15	Strategic Science & Technologies, LLC	Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder strategicscience.com ↗
2018-02-12	Strategic Science & Technologies, LLC	Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder Company enters into license agreement with Strategic Science & Technologies, LLC to develop Topical Sildenafil, now in Phase 2 clinical studies strategicscience.com ↗
2017-12-11	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Exclusive Launch of a Generic Version Viagra® Tablets in the United States tevapharm.com ↗
2015-11-05	Gilead Sciences	U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗
2015-10-28	Strategic Science & Technologies, LLC	Strategic Science & Technologies (SST) Initiates Phase 2 Study to Evaluate Topical Sildenafil in Women with Female Sexual Arousal Disorder SST-6007 is a first-in-class topical sildenafil product candidate in development as an over-the-counter treatment for Female Sexual Arousal Disorder strategicscience.com ↗
2015-06-17	Strategic Science & Technologies, LLC	Strategic Science & Technologies, LLC (SST) Initiates Phase 2 Study to Evaluate Topical Sildenafil in Men with Erectile Dysfunction SST-6006 is a first-in-class topical sildenafil product candidate in development as an over-the- counter treatment for erectile dysfunction strategicscience.com ↗
2015-05-15	Strategic Science & Technologies, LLC	Strategic Science & Technologies, LLC (SST) announces completion of its Phase 1 clinical trial for SST-6007, a first-in-class topical sildenafil cream, to treat female sexual arousal disorder ------------------------------------------------ • SST-6007 was well tolerated in healthy subjects, with no dermal irritation observed at clinically relevant doses • SST-6007 successfully delivered sildenafil to the local target tissue • SST-6007 was systemically absorbed into the bloodstream, but at significantly reduced levels compared to the marketed oral formulation of sildenafil (Viagra®) ------------------------------------------------ strategicscience.com ↗
2013-12-17	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Settles Viagra® Patent Litigation with Pfizer tevapharm.com ↗
2013-06-24	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches Generic Version of Viagra® (sildenafil) in Countries Across Europe tevapharm.com ↗
2007-08-10	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval Of Sildenafil Citrate Tablets, 20 Mg tevapharm.com ↗
2005-04-18	Eli Lilly and Company	Cialis(R) (tadalafil) Overtakes Viagra to Become Number One Selling Erectile Dysfunction Treatment in France lilly.com ↗

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 423 sources stand behind the page.

Field	Value	Cited text
Known as	sildenafil	“Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED)...” NCT01063855 ↗ 373 “All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one...” NCT06317805 ↗ “This is a single dose open-label comparative pharmacokinetic study to assess the pharmacokinetic characteristics of sildenafil between HIP0908 (chewable tablet) and Viagra...” NCT01514903 ↗ “A Phase 1 Pharmacokinetic/Bioequivalence Study of 100 Mg of HEZKUE® (ASP-001, Sildenafil) Versus 100 Mg of VIAGRA® (Sildenafil) Film-Coated Tablets Under Fasted Conditions in...” NCT06782659 ↗ “The objective of this study was to evaluate the effects of a triple combination of leucine, metformin, and sildenafil (NS-0200) on body weight and obesity comorbidities in a...” PMID 30569637 ↗ Jan 2019 “patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.” NCT05741229 ↗ “Sildenafil is efficacious in newborns with persistent pulmonary hypertension and its use will reduce the need for inhaled nitric oxide.” NCT01069861 ↗ “The PDE-5 inhibitor, sildenafil, is approved for use in patients with PAH and commonly used in the initial treatment for PAH.” NCT01409122 ↗ “Sildenafil (REVATIO®) was approved for the treatment of adult Pulmonary Arterial Hypertension (PAH) in the US and the EU.” PMID 31538282 ↗ Sep 2019 “two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin” NCT03364335 ↗ “Sildenafil is an effective treatment for male penile erectile dysfunction that inhibits the breakdown cGMP.” NCT00479908 ↗ Show 363 more sources
Known as	ASP-001	“A Phase 1 Pharmacokinetic/Bioequivalence Study of 100 Mg of HEZKUE® (ASP-001, Sildenafil) Versus 100 Mg of VIAGRA® (Sildenafil) Film-Coated Tablets Under Fasted Conditions in...” NCT06782659 ↗
Known as	Hezkue	“Hezkue® oral sildenafil suspension will be administered as a single oral dose following controlled moderate alcohol consumption under fasting or standardized conditions,...” NCT07302698 ↗ 2 “A Phase 1 Pharmacokinetic/Bioequivalence Study of 100 Mg of HEZKUE® (ASP-001, Sildenafil) Versus 100 Mg of VIAGRA® (Sildenafil) Film-Coated Tablets Under Fasted Conditions in...” NCT06782659 ↗ “Hezkue® sildenafil oral suspension will be administered as a single oral dose in each study period under different alcohol intake conditions” NCT07290400 ↗
Known as	Respatio	“Sildenafil citrate (trade name: Revatio, Viagra, Respatio, etc.) was emerged as a drug helping vasodilation” NCT06565728 ↗
Known as	Respatio(R)	“Includes 45 women who received Sildenafil citrate (Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period) and folic acid...” NCT03766594 ↗
Known as	Revatio	“Sildenafil, commonly known as Revatio or Viagra, is a medication that increases the supply of blood to the lungs and reduces the workload of the heart.” NCT00763867 ↗ 8 “Sildenafil (REVATIO®) was approved for the treatment of adult Pulmonary Arterial Hypertension (PAH) in the US and the EU.” PMID 31538282 ↗ Sep 2019 “Effects of Sildenafil Citrate (Revatio) 20 mg TID on Patients With Portal Pulmonary Arterial Hypertension (PPAH)” NCT01517854 ↗ “Sildenafil citrate (trade name: Revatio, Viagra, Respatio, etc.) was emerged as a drug helping vasodilation” NCT06565728 ↗ “the drug sildenafil (Revatio®) can improve muscular, cardiac, cerebrovascular or cognitive function” NCT01350154 ↗ “Sildenafil (Revatio®) an inhibitor of the phosphodiesterase 5 (PDE-5)” NCT00586794 ↗ “Active Drug: Sildenafil tablets (Revatio)” NCT02335242 ↗ “sildenafil (Revatio) 20 mg TID” NCT00866983 ↗ NCT01027117 ↗
Known as	Revation	“Sildenafil (Revation) 20 mg” NCT01350154 ↗
Known as	silden	“sildenafil (silden® 25, E.I.P.I.CO.)” NCT03301233 ↗
Known as	Sildenafil Citrate	“A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female...” NCT00644631 ↗ 85 “A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil...” NCT00249730 ↗ “A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra...” NCT00644956 ↗ “Viagra (Sildenafil citrate) is an orally active selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) which is used for the...” NCT01315262 ↗ “A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile...” NCT00645268 ↗ “An Open Label, Multicenter Study to Measure Treatment Responsiveness of Quality of Sexual Life Questionnaire in the Female Partner of Men With Erectile Dysfunction Treated With...” NCT00245596 ↗ “An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra...” NCT00151463 ↗ “One hour before each study part, a pharmacy produced capsule (envelope coded and drawn in a random manner from a box) containing either sildenafil citrate 50 mg or placebo will...” NCT00772135 ↗ “Sildenafil citrate is a phosphodiesterase-5 (PDE-5) inhibitor that is FDA-approved and widely used as a therapy for primary pulmonary hypertension and erectile dysfunction.” NCT05782244 ↗ “The phosphodiesterase 5 inhibitor, sildenafil citrate, slightly reduces systolic and diastolic blood pressures in treated hypertensives patients.” NCT01392638 ↗ “Among premature infants with severe BPD, enteral sildenafil citrate did not increase the incidence of hypotension or retinopathy of prematurity.” PMID 42105936 ↗ May 2026 Show 75 more sources
Known as	Sildenafil Citrate 20 mg ( Respatio 20 mg)	“Sildenafil Citrate 20 mg ( Respatio® 20 mg)” NCT03262961 ↗
Known as	SST-6006	“5% Sildenafil Cream (SST-6006)” NCT01986673 ↗
Known as	SST-6007	“SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate” NCT02570282 ↗
Known as	UK-92,480	“sildenafil citrate (UK-92,480)” NCT00454207 ↗
Known as	Viagra	“The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer...” NCT05558176 ↗ 48 “A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female...” NCT00644631 ↗ “A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra...” NCT00644956 ↗ “Viagra (Sildenafil citrate) is an orally active selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) which is used for the...” NCT01315262 ↗ “Does pre-operative administration of Sildenafil (Viagra, Pfizer) reduce the lung injury associated with cardiopulmonary bypass in children undergoing corrective surgical repair...” NCT00350441 ↗ “A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile...” NCT00645268 ↗ “An Open Label, Multicenter Study to Measure Treatment Responsiveness of Quality of Sexual Life Questionnaire in the Female Partner of Men With Erectile Dysfunction Treated With...” NCT00245596 ↗ “A Phase 1 Pharmacokinetic/Bioequivalence Study of 100 Mg of HEZKUE® (ASP-001, Sildenafil) Versus 100 Mg of VIAGRA® (Sildenafil) Film-Coated Tablets Under Fasted Conditions in...” NCT06782659 ↗ “An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra...” NCT00151463 ↗ “In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months of the smoking...” NCT03382106 ↗ “To compare the efficacy and safety of Viagra (sildenafil citrate) vs. placebo for the treatment of men with ED and at least 1 prespecified risk factor who do not self identify...” NCT00343200 ↗ Show 38 more sources
Known as	Viagra(R)	“Sildenafil (Viagra(R))is widely used by men with Parkinsons Disease (PD) and erectile dysfunction.” NCT01941732 ↗
Action	Inhibit	“sildenafil (Viagra, a phosphodiesterase inhibitor that potentates cGMP dependent signaling)” NCT00056433 ↗
Route	Oral	“oral L-arginine (the substrate for NO synthase) and sildenafil (Viagra, a phosphodiesterase inhibitor that potentates cGMP dependent signaling) will be added” NCT00056433 ↗
Target	CYP3A4	“sildenafil a CYP3A4 substrate and inhibitor” NCT04170790 ↗